[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597077":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":21,"locations":27,"responsibleParty":138,"collaborators":140,"id":143,"slug":144,"hasResults":145,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":145,"sex":151,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":11,"studyType":157,"phases":158,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Autolus Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Obe-cel","EXPERIMENTAL",null,[13],"Biological: Obecabtagene autoleucel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Obecabtagene autoleucel","Obecabtagene autoleucel (obe-cel) given as a single infusion",[9],[9],[22],{"name":23,"role":24,"phone":25,"phoneExt":11,"email":26},"Autolus Ltd","CONTACT","+44 (0)203 911 4385","clinicaltrials@autolus.com",[28,42,52,66,78,90,102,114,123,129],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":11},"State University of New York Upstate Medical Center (SUNY)","RECRUITING","Syracuse","New York","13210","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-76.14742,43.04812,{"lat":40,"lon":39},{"facility":43,"status":30,"city":44,"state":45,"zip":46,"country":34,"countryCode":35,"cosmosGeoPoint":47,"geoPoint":51,"contacts":11},"Texas Transplant Institute","San Antonio","Texas","78229",{"type":37,"coordinates":48},[49,50],-98.49363,29.42412,{"lat":50,"lon":49},{"facility":53,"status":30,"city":54,"state":11,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Queen Elizabeth Hospital Birmingham","Birmingham","B15 2TH","United Kingdom","UK",{"type":37,"coordinates":59},[60,61],-1.89983,52.48142,{"lat":61,"lon":60},[64],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":65},"UHBHaematologyResearchTeam@uhb.nhs.uk",{"facility":67,"status":30,"city":68,"state":11,"zip":69,"country":56,"countryCode":57,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Bristol Haematology and Oncology Centre","Bristol","BS1 3LH",{"type":37,"coordinates":71},[72,73],-2.59665,51.45523,{"lat":73,"lon":72},[76],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":77},"BHOCClinicalTrials@uhbw.nhs.uk",{"facility":79,"status":30,"city":80,"state":11,"zip":81,"country":56,"countryCode":57,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Addenbrooke's Hospital","Cambridge","CB2 0QQ",{"type":37,"coordinates":83},[84,85],0.11667,52.2,{"lat":85,"lon":84},[88],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":89},"fatemeh.alemi@nhs.net",{"facility":91,"status":30,"city":92,"state":11,"zip":93,"country":56,"countryCode":57,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Western General Hospital Edinburgh","Edinburgh","EH4 2XU",{"type":37,"coordinates":95},[96,97],-3.19648,55.95206,{"lat":97,"lon":96},[100],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":101},"loth.rdoffice@nhs.scot",{"facility":103,"status":30,"city":104,"state":11,"zip":105,"country":56,"countryCode":57,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Queen Elizabeth University Hospital","Glasgow","G51 4TF",{"type":37,"coordinates":107},[108,109],-4.25763,55.86515,{"lat":109,"lon":108},[112],{"name":11,"role":24,"phone":11,"phoneExt":11,"email":113},"ggc.glasgowcrf.generic@nhs.scot",{"facility":115,"status":30,"city":116,"state":11,"zip":117,"country":56,"countryCode":57,"cosmosGeoPoint":118,"geoPoint":122,"contacts":11},"University College Hospital","London","MW1 2PG",{"type":37,"coordinates":119},[120,121],-0.12574,51.50853,{"lat":121,"lon":120},{"facility":124,"status":30,"city":116,"state":11,"zip":125,"country":56,"countryCode":57,"cosmosGeoPoint":126,"geoPoint":128,"contacts":11},"Great Ormond Street Hospital","WC1N 3JH",{"type":37,"coordinates":127},[120,121],{"lat":121,"lon":120},{"facility":130,"status":30,"city":131,"state":11,"zip":132,"country":56,"countryCode":57,"cosmosGeoPoint":133,"geoPoint":137,"contacts":11},"Manchester Royal Infirmary","Manchester","M13 9WL",{"type":37,"coordinates":134},[135,136],-2.23743,53.48095,{"lat":136,"lon":135},{"type":139,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[141],{"name":142,"class":6},"PPD Development, LP","100597077","phase-2-obe-cel-in-severe-refractory-systemic-lupus-erythematosus-sle-with-active-lupus-nephritis-ln-100597077",false,"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)","A Single-Arm, Open-Label, Phase II Study to Determine the Safety and Efficacy of Obecabtagene Autoleucel (Obe-cel) in Participants With Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis","LUMINA","Inclusion Criteria:\n\n* Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative\n* Ability and willingness to adhere to protocol's Schedule of Activities and other requirements\n* Participants must be 12 to 65 years of age inclusive at the time of signing the informed consent.\n* Female Participants: - a female participant is eligible to participate if she is not pregnant or breastfeeding\n* Diagnosis of SLE fulfilling the 2019 European League Against Rheumatism (EULAR)\u002FAmerican College of Rheumatology (ACR) Classification Criteria for Systemic Lupus Erythematosus.\n* Positive for at least 1 of the following autoantibodies: antinuclear antibodies (ANA), or anti-dsDNA or anti-Smith.\n* Severe, Active SLE defined as:\n\n  * SLEDAI-2K score of ≥ 8 points AND\n  * Severe active LN based on a renal biopsy: Class III, IV or V (V only in combination with class III or IV)\n* Refractory SLE defined as failure to previous lines of therapy\n\nExclusion Criteria:\n\n* Prior treatment at any time with anti-CD19 therapy\n* More than 1 acute, severe lupus-related flare during screening that needs immediate treatment and\u002For makes the immunosuppressive washout impossible\n* Significant, likely irreversible organ damage related to SLE (e.g., end-stage renal disease) that in the opinion of the Investigator renders CD19 CAR T cell therapy unlikely to benefit the participant\n* History of primary antiphospholipid antibody syndrome\n* Active or uncontrolled fungal, bacterial, or viral infection\n* History of malignant neoplasms unless disease free for at least 24 months\n* History of heart, lung, renal, liver transplant or hematopoietic stem cell transplant","ALL","12 Years","65 Years",{"count":155,"type":156},35,"ESTIMATED","INTERVENTIONAL",[159],"PHASE2","The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).",[162],"Lupus Nephritis",[164,165,166,17,9],"Systemic lupus erythematosus","Refractory systemic lupus erythematosus","Lupus nephritis","2026-06-19",{"date":169,"type":170},"2026-06-23","ACTUAL",{"date":172,"type":170},"2026-01-16",{"date":174,"type":156},"2029-10",{"name":5,"class":6},10]